KNOTUS Co.Ltd (278650) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.083x

Based on the latest financial reports, KNOTUS Co.Ltd (278650) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.34 Billion ≈ $-6.33 Million USD) by net assets (₩112.17 Billion ≈ $76.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 278650 net asset quality index to measure how much of total assets are equity-financed.

KNOTUS Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how KNOTUS Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is KNOTUS Co.Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

KNOTUS Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of KNOTUS Co.Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Positivo Tecnologia S.A
SA:POSI3
0.073x
XAC Automation
TWO:5490
0.082x
Multicampus Corporation
KQ:067280
0.027x
SNC Former Public Company Limited
BK:SNC
0.028x
CareCloud, Inc.
NASDAQ:CCLD
0.062x
Quantum Foods Holdings
JSE:QFH
0.032x
Black Diamond Therapeutics Inc
NASDAQ:BDTX
-0.098x
Railcare Group AB (publ)
ST:RAIL
0.232x

Annual Cash Flow Conversion Efficiency for KNOTUS Co.Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of KNOTUS Co.Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of KNOTUS Co.Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩111.87 Billion
≈ $75.82 Million
₩-11.67 Billion
≈ $-7.91 Million
-0.104x -308.10%
2023-12-31 ₩103.57 Billion
≈ $70.19 Million
₩5.19 Billion
≈ $3.52 Million
0.050x -45.64%
2022-12-31 ₩70.28 Billion
≈ $47.63 Million
₩6.48 Billion
≈ $4.39 Million
0.092x -29.62%
2021-12-31 ₩64.59 Billion
≈ $43.77 Million
₩8.46 Billion
≈ $5.74 Million
0.131x -38.68%
2020-12-31 ₩53.64 Billion
≈ $36.35 Million
₩11.46 Billion
≈ $7.77 Million
0.214x +72.64%
2019-12-31 ₩41.86 Billion
≈ $28.37 Million
₩5.18 Billion
≈ $3.51 Million
0.124x -50.63%
2018-12-31 ₩20.67 Billion
≈ $14.01 Million
₩5.18 Billion
≈ $3.51 Million
0.251x -22.38%
2017-12-31 ₩16.04 Billion
≈ $10.87 Million
₩5.18 Billion
≈ $3.51 Million
0.323x -13.89%
2016-12-31 ₩8.36 Billion
≈ $5.66 Million
₩3.13 Billion
≈ $2.12 Million
0.375x --

About KNOTUS Co.Ltd

KQ:278650 Korea Biotechnology
Market Cap
$96.91 Million
₩143.01 Billion KRW
Market Cap Rank
#19231 Global
#916 in Korea
Share Price
₩1693.00
Change (1 day)
+6.95%
52-Week Range
₩1099.00 - ₩4785.00
All Time High
₩36886.01
About

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more